Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 6, 2008, Pages 1535-1542

  Byrd, Louise M ^a,b   Shenton, Andrew ^b   Maher, Eamonn R ^c   Woodward, Emma ^c   Belk, Rachel ^a   Lim, Caron ^a   Lalloo, Fiona ^a,b   Howell, Anthony ^a   Jayson, Gordon C ^a   Evans, Gareth D ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BRCA2 GENE; FEMALE; GENE FREQUENCY; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; ONCOGENE; ONSET AGE; OVARY CANCER; PATHOGENESIS; PREMATURITY; PRIORITY JOURNAL; RELATIVE; RISK ASSESSMENT; SURVIVAL TIME; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ENGLAND; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; INCIDENCE; LIFE EXPECTANCY; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 53349100166     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2792     Document Type: Article

References (26)

1. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465-71.
2. Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 2004;22:1045-54.
3. Ford D, Easton M, Stratton S, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
4. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000;83:1301-8.
5. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
6. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risk of cancer in BRCA-1 mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:92-695.
7. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
8. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-6.
9. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 2001;21:1-18.
10. Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:1241-7.
11. Hopper JL, Southey MC, Dite GS, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8:741-7.
12. Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with mutations in BRCA1 or BRCA2 detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
13. Evans DG, Howell A. Are BRCA1- and BRCA2-related breast cancers associated with increased mortality? Breast Cancer Res 2004;6:E7.
14. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:115-23.
15. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008;26:20-5.
16. Connor F, Bertwistle D, Mee PJ, et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet 1997;17:423-30.
17. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-95.
18. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001;7:263-72.
19. Tutt A, Bertwistle D, Valentine J, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001;20:4704-16.
20. Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
21. Yu VP, Koehler M, Steinlein C, et al. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev 2000;14:1400-6.
22. Board RE, Bruijns CT, Pronk AE, et al. Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center. Int J Gynecol Cancer 2006;16 Suppl 1:18-24.
23. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004;22:1315-27.
24. Stirling D, Evans DG, Pichert G, et al. Familial Ovarian Cancer Screening: current protocols are ineffective in detecting early stage ovarian malignancy. J Clin Oncol 2005;23:5588-96.
25. Gaarenstroom KN, van der Hiel B, Tollenaar RA, et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 2006;16 Suppl 1:54-9.
26. Jacobs IJ, Mackay J, Menon U, Skates SJ, Rosenthal AN, Fraser L. Familial ovarian screening - effective or ineffective? Br J Cancer 2006;95:1124.